Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies

CONCLUSION: Selinexor-based regimens may offer effective and well-tolerated therapy to patients with relapsed and/or refractory MM who had disease previously exposed or refractory to αCD38 mAb therapy and could help address the unmet clinical need in these high-risk patients.PMID:37393120 | DOI:10.1016/j.clml.2023.06.001

Source: Clinical Lymphoma and Myeloma - July 1, 2023 Category: Cancer & Oncology Authors: Gary J Schiller Brea C Lipe Nizar J Bahlis Sascha A Tuchman William I Bensinger Heather J Sutherland Suzanne Lentzsch Muhamed Baljevic Darrell White Rami Kotb Christine I Chen Adriana Rossi Noa Biran Richard LeBlanc Sebastian Grosicki Maurizio Martelli Eb Source Type: research